Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 3

Decera Clinical Education Oncology Podcast · Sep 17, 2020 · 14m

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:

• The impact of COVID-19 on CLL treatment decisions

• The use of anti-CD20 antibodies in combination with BTK inhibitors

• Considerations when recommending BTK inhibitors

• MRD testing in patients with CLL

• The potential impact of targeted therapies on when to start treatment

Presenters:

Jeff P. Sharman, MD, Program Director

Medical Director

Hematology Research

US…